Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine
Autore:
Raedler, TJ; Knable, MB; Lafargue, T; Urbina, RA; Egan, MF; Pickar, D; Weinberger, DR;
Indirizzi:
NIMH, Clin Brain Disorders Branch, Bethesda, MD 20892 USA NIMH Bethesda MD USA 20892 Brain Disorders Branch, Bethesda, MD 20892 USA NIMH, Expt Therapeut Branch, Bethesda, MD 20892 USA NIMH Bethesda MD USA 20892 Expt Therapeut Branch, Bethesda, MD 20892 USA
Titolo Testata:
PSYCHIATRY RESEARCH-NEUROIMAGING
fascicolo: 2, volume: 90, anno: 1999,
pagine: 81 - 90
SICI:
0925-4927(19990426)90:2<81:IVDOSD>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
PHOTON-EMISSION TOMOGRAPHY; ATYPICAL ANTIPSYCHOTIC OLANZAPINE; DOUBLE-BLIND; SCHIZOPHRENIC-PATIENTS; IN-VIVO; NEGATIVE SYMPTOMS; BASAL GANGLIA; HUMAN BRAIN; HALOPERIDOL; CLOZAPINE;
Keywords:
dopamine D-2 receptor; olanzapine; [I-123]IBZM SPECT; schizophrenia; antipsychotic;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
49
Recensione:
Indirizzi per estratti:
Indirizzo: Weinberger, DR NIMH,SAlin Brain Disorders Branch, Bldg 10,Room 4S235, Bethesda, MD 20892 U NIMH Bldg 10,Room 4S235 Bethesda MD USA 20892 a, MD 20892 U
Citazione:
T.J. Raedler et al., "In vivo determination of striatal dopamine D-2 receptor occupancy in patients treated with olanzapine", PSYCH RES-N, 90(2), 1999, pp. 81-90

Abstract

In vivo studies of dopamine D-2 receptor occupancy with atypical antipsychotics have suggested good clinical efficacy at occupancy rates less than those observed with typical neuroleptics, and few extrapyramidal side effects(EPS), possibly even at high levels of D-2 occupancy. We used [I-123]IBZM-SPECT to investigate striatal D-2 receptor occupancy in 10 schizophrenic patients who were treated with both a low (5 mg) and a high dose (20 mg) of the novel antipsychotic olanzapine without concomitant medications. The meanD-2 occupancy at 5 mg was 59.8% (range 33-81%); the mean D-2 occupancy at 20 mg was 82.8% (range 56-97%). Although the D-2 occupancy rates on 5 and 20 mg olanzapine were significantly different (P < 0.001), there were no significant differences in clinical ratings for psychiatric symptoms or extrapyramidal side effects between the two doses of olanzapine. These data suggest that: (1) olanzapine doses below those used routinely occupy D-2 receptors at levels approaching those associated with therapeutic response; (2) higher doses produce relatively high levels of D-2 occupancy rates; and (3) EPS are mild even at relatively high levels of D-2 occupancy. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 21/09/20 alle ore 18:09:14